Company news
Theralink Technologies Inc. news in 2018
Theralink Technologies Inc.'s news releases, calls and decks from 2018, newest first.
OncBioMune Initiates Phase 2 Clinical Trial of Novel Vaccine as Front-Line Treatment for Prostate Cancer
September 27, 2018
OncBioMune’s Phase 2 Clinical Trial of ProscaVax for Early-Stage Prostate Cancer is Now Included on ClinicalTrials.gov
July 9, 2018
OncBioMune Signs Work Order for Phase 2 Clinical Trial of ProscaVax for Early Stage Prostate Cancer
July 2, 2018
OncBioMune to Commence Phase 2 Trial of ProscaVax for Early Stage Prostate Cancer Patients
June 20, 2018
OncBioMune Returns Protocol to Scientific Review Committee Overseeing Phase 2 Prostate Cancer Clinical Trial
March 28, 2018
Scientific Review Committee Meets on OncBioMune’s Phase 2 Prostate Cancer Clinical Trial
March 22, 2018
OncBioMune Announces Presentation at the 2018 AACR Annual Meeting
March 20, 2018
OncBioMune Appoints Robert Neal Holcomb to Board of Directors
March 19, 2018
OncBioMune Selects Theradex as CRO for Two Phase 2 Trials of ProscaVax for Prostate Cancer
March 8, 2018
OncBioMune Submits Phase 2 Protocol to Urology Centers of North Texas
February 28, 2018
OncBioMune Provides Updates on two Phase 2 Clinical Trials of ProscaVax for Prostate Cancer
February 26, 2018
OncBioMune Provides Update on Market Activity
February 16, 2018
OncBioMune Signs Letter of Intent to Initiate Phase 2 Trial of ProscaVax for Advanced Prostate Cancer with Urology Clinics of North Texas
February 5, 2018
70% of Advanced Prostate Cancer Patients Treated with ProscaVax Demonstrate Improvement in PSA Doubling Time
January 10, 2018